Aurora and Curaleaf Escalate Hostile Takeover Battle
The hostile takeover bid by Curaleaf for Aurora is intensifying, with both companies exchanging public criticisms. Curaleaf has released a second rebuttal to Aurora's arguments against its $4-per-share offer, which values the deal at approximately $272 million and remains open until December 1. Curaleaf CEO Boris Jordan accused Aurora of avoiding negotiations while Aurora’s Miguel Martin urged shareholders to focus on existing value rather than accept what he called an undervalued bid. Aurora highlights its strong cash position with no debt, contrasting it against Curaleaf's $1 billion in liabilities and lease obligations. The dispute centers around valuation claims—Curaleaf argues the offer is a 45% premium over Aurora’s stock price while Aurora disputes these figures as inflated. A key strategic asset for Aurora appears to be its EU-GMP certified facilities, which provide access to growing European medical cannabis markets. Both companies are now debating who is diluting shareholder value and what constitutes meaningful engagement in negotiations.
Topics: cannabis industry shareholder communication takeover battle